Loading…
GP73 contributes to the sensitivity of cisplatin in esophageal cancer
Background The prognosis of esophageal cancer patients is poor. Cisplatin (CDDP) is most often used for advanced esophageal cancer; however, the emergence of drug resistance has prevented successful treatment in many cases. Methods Using microarray analysis, we identified GP73 as a candidate gene th...
Saved in:
| Published in: | Esophagus : official journal of the Japan Esophageal Society 2009-09, Vol.6 (3), p.173-176 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c316t-8162bdd6bf75a7a401bf9a7da24d459802d100a4548e93b8bba1d3d0c2026ddb3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c316t-8162bdd6bf75a7a401bf9a7da24d459802d100a4548e93b8bba1d3d0c2026ddb3 |
| container_end_page | 176 |
| container_issue | 3 |
| container_start_page | 173 |
| container_title | Esophagus : official journal of the Japan Esophageal Society |
| container_volume | 6 |
| creator | Katada, Takeyasu Ishiguro, Hideyuki Kimura, Masahiro Mitui, Akira Harata, Koshiro Ogawa, Ryo Kuwabara, Yoshiyuki |
| description | Background
The prognosis of esophageal cancer patients is poor. Cisplatin (CDDP) is most often used for advanced esophageal cancer; however, the emergence of drug resistance has prevented successful treatment in many cases.
Methods
Using microarray analysis, we identified
GP73
as a candidate gene that is overexpressed in TE4, an esophageal cancer cell line which is highly resistant to CDDP. We downregulated
GP73
expression in TE4 using siRNA methods. To determine the effect of reduced
GP73
expression on the proliferation of TE4, we used cytotoxicity assays.
Results
Downregulation of
GP73
expression using siRNA induced a significant decrease in the IC
50
compared with cells treated with either control siRNA or mock transfection.
Conclusions
GP73
is a candidate gene in esophageal cancer that may be the target of future molecular-targeted therapy in combination with CDDP. |
| doi_str_mv | 10.1007/s10388-009-0201-4 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2494577807</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2494577807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-8162bdd6bf75a7a401bf9a7da24d459802d100a4548e93b8bba1d3d0c2026ddb3</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMoWKs_wF3AdfTmMZPMUkqtQkEXug55TTulzoxJKvTfGxnRlXDh3sU553I-hK4p3FIAeZcocKUIQEOAASXiBM1oTRlpoJanv3fVnKOLlHYAnAnFZ2i5epEcu6HPsbOHHBLOA87bgFPoU5e7zy4f8dBi16Vxb3LX4zIhDePWbILZY2d6F-IlOmvNPoWrnz1Hbw_L18UjWT-vnhb3a-I4rTNRtGbW-9q2sjLSCKC2bYz0hgkvqkYB86WMEZVQoeFWWWuo5x4cA1Z7b_kc3Uy5Yxw-DiFlvRsOsS8vNRONqKRUIIuKTioXh5RiaPUYu3cTj5qC_qalJ1q60NLftLQoHjZ5UtH2mxD_kv83fQERNWw7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2494577807</pqid></control><display><type>article</type><title>GP73 contributes to the sensitivity of cisplatin in esophageal cancer</title><source>Springer Link</source><creator>Katada, Takeyasu ; Ishiguro, Hideyuki ; Kimura, Masahiro ; Mitui, Akira ; Harata, Koshiro ; Ogawa, Ryo ; Kuwabara, Yoshiyuki</creator><creatorcontrib>Katada, Takeyasu ; Ishiguro, Hideyuki ; Kimura, Masahiro ; Mitui, Akira ; Harata, Koshiro ; Ogawa, Ryo ; Kuwabara, Yoshiyuki</creatorcontrib><description>Background
The prognosis of esophageal cancer patients is poor. Cisplatin (CDDP) is most often used for advanced esophageal cancer; however, the emergence of drug resistance has prevented successful treatment in many cases.
Methods
Using microarray analysis, we identified
GP73
as a candidate gene that is overexpressed in TE4, an esophageal cancer cell line which is highly resistant to CDDP. We downregulated
GP73
expression in TE4 using siRNA methods. To determine the effect of reduced
GP73
expression on the proliferation of TE4, we used cytotoxicity assays.
Results
Downregulation of
GP73
expression using siRNA induced a significant decrease in the IC
50
compared with cells treated with either control siRNA or mock transfection.
Conclusions
GP73
is a candidate gene in esophageal cancer that may be the target of future molecular-targeted therapy in combination with CDDP.</description><identifier>ISSN: 1612-9059</identifier><identifier>EISSN: 1612-9067</identifier><identifier>DOI: 10.1007/s10388-009-0201-4</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Esophageal cancer ; Esophagus ; Gastroenterology ; Medical prognosis ; Medicine ; Medicine & Public Health ; Original Article ; Surgical Oncology ; Thoracic Surgery</subject><ispartof>Esophagus : official journal of the Japan Esophageal Society, 2009-09, Vol.6 (3), p.173-176</ispartof><rights>Japan Esophageal Soceity and Springer Japan 2009</rights><rights>Japan Esophageal Soceity and Springer Japan 2009.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c316t-8162bdd6bf75a7a401bf9a7da24d459802d100a4548e93b8bba1d3d0c2026ddb3</citedby><cites>FETCH-LOGICAL-c316t-8162bdd6bf75a7a401bf9a7da24d459802d100a4548e93b8bba1d3d0c2026ddb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Katada, Takeyasu</creatorcontrib><creatorcontrib>Ishiguro, Hideyuki</creatorcontrib><creatorcontrib>Kimura, Masahiro</creatorcontrib><creatorcontrib>Mitui, Akira</creatorcontrib><creatorcontrib>Harata, Koshiro</creatorcontrib><creatorcontrib>Ogawa, Ryo</creatorcontrib><creatorcontrib>Kuwabara, Yoshiyuki</creatorcontrib><title>GP73 contributes to the sensitivity of cisplatin in esophageal cancer</title><title>Esophagus : official journal of the Japan Esophageal Society</title><addtitle>Esophagus</addtitle><description>Background
The prognosis of esophageal cancer patients is poor. Cisplatin (CDDP) is most often used for advanced esophageal cancer; however, the emergence of drug resistance has prevented successful treatment in many cases.
Methods
Using microarray analysis, we identified
GP73
as a candidate gene that is overexpressed in TE4, an esophageal cancer cell line which is highly resistant to CDDP. We downregulated
GP73
expression in TE4 using siRNA methods. To determine the effect of reduced
GP73
expression on the proliferation of TE4, we used cytotoxicity assays.
Results
Downregulation of
GP73
expression using siRNA induced a significant decrease in the IC
50
compared with cells treated with either control siRNA or mock transfection.
Conclusions
GP73
is a candidate gene in esophageal cancer that may be the target of future molecular-targeted therapy in combination with CDDP.</description><subject>Esophageal cancer</subject><subject>Esophagus</subject><subject>Gastroenterology</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article</subject><subject>Surgical Oncology</subject><subject>Thoracic Surgery</subject><issn>1612-9059</issn><issn>1612-9067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp1kEtLAzEUhYMoWKs_wF3AdfTmMZPMUkqtQkEXug55TTulzoxJKvTfGxnRlXDh3sU553I-hK4p3FIAeZcocKUIQEOAASXiBM1oTRlpoJanv3fVnKOLlHYAnAnFZ2i5epEcu6HPsbOHHBLOA87bgFPoU5e7zy4f8dBi16Vxb3LX4zIhDePWbILZY2d6F-IlOmvNPoWrnz1Hbw_L18UjWT-vnhb3a-I4rTNRtGbW-9q2sjLSCKC2bYz0hgkvqkYB86WMEZVQoeFWWWuo5x4cA1Z7b_kc3Uy5Yxw-DiFlvRsOsS8vNRONqKRUIIuKTioXh5RiaPUYu3cTj5qC_qalJ1q60NLftLQoHjZ5UtH2mxD_kv83fQERNWw7</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Katada, Takeyasu</creator><creator>Ishiguro, Hideyuki</creator><creator>Kimura, Masahiro</creator><creator>Mitui, Akira</creator><creator>Harata, Koshiro</creator><creator>Ogawa, Ryo</creator><creator>Kuwabara, Yoshiyuki</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20090901</creationdate><title>GP73 contributes to the sensitivity of cisplatin in esophageal cancer</title><author>Katada, Takeyasu ; Ishiguro, Hideyuki ; Kimura, Masahiro ; Mitui, Akira ; Harata, Koshiro ; Ogawa, Ryo ; Kuwabara, Yoshiyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-8162bdd6bf75a7a401bf9a7da24d459802d100a4548e93b8bba1d3d0c2026ddb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Esophageal cancer</topic><topic>Esophagus</topic><topic>Gastroenterology</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article</topic><topic>Surgical Oncology</topic><topic>Thoracic Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katada, Takeyasu</creatorcontrib><creatorcontrib>Ishiguro, Hideyuki</creatorcontrib><creatorcontrib>Kimura, Masahiro</creatorcontrib><creatorcontrib>Mitui, Akira</creatorcontrib><creatorcontrib>Harata, Koshiro</creatorcontrib><creatorcontrib>Ogawa, Ryo</creatorcontrib><creatorcontrib>Kuwabara, Yoshiyuki</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Esophagus : official journal of the Japan Esophageal Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katada, Takeyasu</au><au>Ishiguro, Hideyuki</au><au>Kimura, Masahiro</au><au>Mitui, Akira</au><au>Harata, Koshiro</au><au>Ogawa, Ryo</au><au>Kuwabara, Yoshiyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GP73 contributes to the sensitivity of cisplatin in esophageal cancer</atitle><jtitle>Esophagus : official journal of the Japan Esophageal Society</jtitle><stitle>Esophagus</stitle><date>2009-09-01</date><risdate>2009</risdate><volume>6</volume><issue>3</issue><spage>173</spage><epage>176</epage><pages>173-176</pages><issn>1612-9059</issn><eissn>1612-9067</eissn><abstract>Background
The prognosis of esophageal cancer patients is poor. Cisplatin (CDDP) is most often used for advanced esophageal cancer; however, the emergence of drug resistance has prevented successful treatment in many cases.
Methods
Using microarray analysis, we identified
GP73
as a candidate gene that is overexpressed in TE4, an esophageal cancer cell line which is highly resistant to CDDP. We downregulated
GP73
expression in TE4 using siRNA methods. To determine the effect of reduced
GP73
expression on the proliferation of TE4, we used cytotoxicity assays.
Results
Downregulation of
GP73
expression using siRNA induced a significant decrease in the IC
50
compared with cells treated with either control siRNA or mock transfection.
Conclusions
GP73
is a candidate gene in esophageal cancer that may be the target of future molecular-targeted therapy in combination with CDDP.</abstract><cop>Japan</cop><pub>Springer Japan</pub><doi>10.1007/s10388-009-0201-4</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1612-9059 |
| ispartof | Esophagus : official journal of the Japan Esophageal Society, 2009-09, Vol.6 (3), p.173-176 |
| issn | 1612-9059 1612-9067 |
| language | eng |
| recordid | cdi_proquest_journals_2494577807 |
| source | Springer Link |
| subjects | Esophageal cancer Esophagus Gastroenterology Medical prognosis Medicine Medicine & Public Health Original Article Surgical Oncology Thoracic Surgery |
| title | GP73 contributes to the sensitivity of cisplatin in esophageal cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T21%3A31%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GP73%20contributes%20to%20the%20sensitivity%20of%20cisplatin%20in%20esophageal%20cancer&rft.jtitle=Esophagus%20:%20official%20journal%20of%20the%20Japan%20Esophageal%20Society&rft.au=Katada,%20Takeyasu&rft.date=2009-09-01&rft.volume=6&rft.issue=3&rft.spage=173&rft.epage=176&rft.pages=173-176&rft.issn=1612-9059&rft.eissn=1612-9067&rft_id=info:doi/10.1007/s10388-009-0201-4&rft_dat=%3Cproquest_cross%3E2494577807%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c316t-8162bdd6bf75a7a401bf9a7da24d459802d100a4548e93b8bba1d3d0c2026ddb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2494577807&rft_id=info:pmid/&rfr_iscdi=true |